Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q1 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Aug 12, 2022 / 03:00AM GMT
Release Date Price: ₹388.8 (-0.05%)
Operator

Good morning, ladies and gentlemen. Welcome to the Q1 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you. And over to you, sir.

Utkarsh Gandhi

Thank you, moderator. Good morning, everyone, and a very warm welcome to the Q1 FY '23 Results Conference Call of Glenmark Pharmaceuticals Limited.

Before we start the call, a review of the operations for the first quarter of FY '23. Glenmark's consolidated revenue from operations for Q1 FY '23 was at INR 27,773 million as against INR 29,649 million in the corresponding quarter last year, recording a decrease of 6.3%. Excluding the global sales of COVID-related products in the first quarter of FY '22, the year-on-year growth in the base business in the current financial year was at 10.4%.

Let's review the performance of the formulation business, starting with India. Sales for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot